Study identifier:NIS-NME-XXX-2011/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A non- interventional study to observe real life usage of atypical antipsychotics in the acute inpatient management of schizophrenia.
schizophrenia
N/A
No
-
All
1050
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Dec 2013 by AstraZeneca
AstraZeneca
-
The primary objective of this Non- Interventional Study (NIS) is to describe the use of atypical antipsychotics in subjects with Schizophrenia during the hospitalisation due to acute psychotic episode by evaluation of drug, dose and mode of administration of the medication.
RECONNECT-S BETA
Location
Location
Abu Dhabi, United Arab Emirates
Location
Ras Al Khaimah, United Arab Emirates
Location
Dubai, United Arab Emirates
Location
Cairo, Egypt
Location
Riyadh, Saudi Arabia
Location
Jeddah, Saudi Arabia
Location
Dammam, Saudi Arabia
Arms | Assigned Interventions |
---|---|
Subjects who are hospitalized due to acute psychotic episode. All subjects who are hospitalized due to acute psychotic episode. The subjects should be managed according to normal clinical practice until discharge time. | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.